MCM
VERA icon

Massar Capital Management’s Vera Therapeutics VERA Stock Holding History

Massar Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,000
Closed -$377K – 215
2025
Q2 		$377K Buy
+16,000
New +$360K 0.28% 78

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massar Capital Management's VERA Position: Q3 2025 in Review

Massar Capital Management sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 16,000 shares — an estimated $377K sold.

Massar Capital Management first reported a position in VERA in Q2 2025 and held it in 1 quarter. The position peaked at $377K in Q2 2025. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • Massar Capital Management reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Massar Capital Management sold 16,000 Vera Therapeutics shares in Q3 2025, an estimated $377K.
  • Massar Capital Management first reported a position in Vera Therapeutics in Q2 2025 and held it in 1 quarter.
  • Massar Capital Management's Vera Therapeutics position peaked at $377K in Q2 2025.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Massar Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.